Possible senolytic agents are under preliminary research, including some which are in
early-stage human trials. The majority of candidate senolytic compounds are repurposed
anti-cancer molecules, such as the
chemotherapeutic drug
dasatinib and the experimental small molecule
navitoclax. Soluble
urokinase plasminogen activator surface receptor have been found to be highly expressed on senescent cells, leading researchers to use
chimeric antigen receptor T cells to eliminate senescent cells in mice. According to reviews, it is thought that senolytics can be administered intermittently while being as effective as continuous administration. This could be an advantage of senolytic drugs and decrease adverse effects, for instance circumventing potential off-target effects.
Senolytic candidates == Senomorphics ==